Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 6, 2007, Pages 841-849

  Song, Hairong ^a   Vita, Marina ^a,b   Sallam, Hatem ^a   Tehranchi, Ramin ^a,c   Nilsson, Christina ^a   Sidén, Åke ^a   Hassan, Zuzana ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Cdk inhibitor; Clonogenic assay; Hematopoietic progenitors; Mouse; Myelosuppression

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DIMETHYL SULFOXIDE; ROSCOVITINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CANCER CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TOXICITY;

ANIMALS; AREA UNDER CURVE; BONE MARROW; BONE MARROW CELLS; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROID PROGENITOR CELLS; FEMALE; GRANULOCYTES; HALF-LIFE; HEMATOPOIETIC STEM CELLS; MICE; MICE, INBRED BALB C; PROTEIN KINASE INHIBITORS; PURINES; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 34548574658     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0431-x     Document Type: Article

References (33)

1. Cheson BD (1995) Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431-2448
2. Cheson BD, Vena DA, Foss FM, Sorensen JM (1994) Neurotoxicity of purine analogs: a review. J Clin Oncol 12:2216-2228
3. Corazza F, Hermans C, Ferster A, Fondu P, Demulder A, Sariban E (2004) Bone marrow stroma damage induced by chemotherapy for acute lymphoblastic leukemia in children. Pediatr Res 55:152-158
4. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243:518-526
5. de la Motte S, Gianella-Borradori A (2004) Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther 42:232-239
6. Gherardi D, D'Agati V, Chu TH, Barnett A, Gianella-Borradori A, Gelman IH, Nelson PJ (2004) Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 15:1212-1222
7. Hahntow IN, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, Peschel C, Decker T (2004) Cyclin-dependent kinase inhibitor roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18:747-755
8. Hajduch M, Kolar Z, Novotny R, Hanus J, Mihal V, Hlobilkova A, Noskova V, Strnad M (1997) Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine. Anticancer Drugs 8:1007-1013
9. Hassan Z, Hassan M, Hellstrom-Lindberg E (2001) The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro. Leukemia 15:1240-1247
10. Hassan Z, Hellstrom-Lindberg E, Alsadi S, Edgren M, Hagglund H, Hassan M (2002) The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. Bone Marrow Transplant 30:141-147
11. Kouroussis C, Souglakos J, Kakolyris S, Mavroudis D, Malamos N, Kalbakis K, Androulakis N, Agelaki A, Vardakis N, Samonis G, Georgoulias V (2001) Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology 61:36-41
12. Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E, Catapano C, Cavalli F, Gianella-Borradori A, Maccallum DE, Bertoni F (2005) In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 16:1169-1176
13. Li BS, Sun MK, Zhang L, Takahashi S, Ma W, Vinade L, Kulkarni AB, Brady RO, Pant HC (2001) Regulation of NMDA receptors by cyclin-dependent kinase-5. Proc Natl Acad Sci USA 98:12742-12747
14. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP, Green SR (2005) Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65:5399-5407
15. Malerba I, Castoldi AF, Parent-Massin D, Gribaldo L (2002) In vitro myelotoxicity of propanil and 3,4-dichloroaniline on murine and human CFU-E/BFU-E progenitors. Toxicol Sci 69:433-438
16. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102:463-468
17. Meijer L, Raymond E (2003) Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 36:417-425
18. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243:527-536
19. Mgbonyebi OP, Russo J, Russo IH (1999) Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res 59:1903-1910
20. Mihara M, Shintani S, Kiyota A, Matsumura T, Wong DT (2002) Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-× in head and neck squamous cell carcinoma cells. Int J Oncol 21:95-101
21. N'Cho M, Brahmi Z (2001) Evidence that Fas-induced apoptosis leads to S phase arrest. Hum Immunol 62:310-319
22. Nutley BP, Raynaud FI, Wilson SC, Fischer PM, Hayes A, Goddard PM, McClue SJ, Jarman M, Lane DP, Workman P (2005) Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther 4:125-139
23. Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P (2005) In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 11:4875-4887
24. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, Caldicott A, Martinez-Losa M, Walker TR, Duffin R, Gray M, Crescenzi E, Martin MC, Brady HJ, Savill JS, Dransfield I, Haslett C (2006) Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 12:1056-1064
25. Samonis G, Kontoyiannis DP (2001) Infectious complications of purine analog therapy. Curr Opin Infect Dis 14:409-413
26. Senderowicz AM (2004) Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 16:670-678
27. Swanton C (2004) Cell-cycle targeted therapies. Lancet Oncol 5:27-36
28. Tirado OM, Mateo-Lozano S, Notario V (2005) Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res 65:9320-9327
29. Vita M, Meurling L, Pettersson T, Cruz-Siden M, Siden A, Hassan M (2004) Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: pharmacokinetics of roscovitine in rat. J Pharm Biomed Anal 34:425-431
30. Vita M, Abdel-Rehim M, Olofsson S, Hassan Z, Meurling L, Siden A, Siden M, Pettersson T, Hassan M (2005) Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur J Pharm Sci 25:91-103
31. Vitali L, Yakisich JS, Vita MF, Fernandez A, Settembrini L, Siden A, Cruz M, Carminatti H, Casas O, Idoyaga Vargas V (2002) Roscovitine inhibits ongoing DNA synthesis in human cervical cancer. Cancer Lett 180:7-12
32. Yakisich JS, Boethius J, Lindblom IO, Wallstedt L, Vargas VI, Siden A, Cruz M (1999) Inhibition of DNA synthesis in human gliomas by roscovitine. Neuroreport 10:2563-2567
33. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, Grant S (2003) The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 63:1822-1833